Xiaohong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaohong Li has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Yamei Wu
The Fifth Medical Center of Chinese PLA General Hospital
2 shared publications - Bei Yan
Beijing Jingdu Children’s Hospital, No. 308 Huilongguan East Street, Changping District, Beijing 102208, China
1 shared publication Fei She
1 shared publicationJianying Guo
1 shared publicationLi Yan
1 shared publicationLiwei Pang
1 shared publication
Latest Publications
- Open Access
- 20 August 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2711554
Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013–2025
Multiple myeloma (MM) is the second most common hematological malignancy globally. In 2022, there were approximately 188,000 new cases and 121,000 deaths attributed to MM worldwide. Projections ind...
- 20 August 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2711554
Open AccessGlobal trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013–2025
Multiple myeloma (MM) is the second most common hematological malignancy globally. In 2022, there were approximately 188,000 new cases and 121,000 deaths attributed to MM worldwide. Projections ind...
- Open Access
- 1 March 2018
- Published by Springer Nature in European Journal of Medical Research
- Vol. 23 (1) , 1-8
Clinical evaluation of haploidentical hematopoietic combined with human umbilical cord-derived mesenchymal stem cells in severe aplastic anemia
This study not only evaluated the clinical effects of treatment using haploidentical hematopoietic stem cells (haplo-HSCs) combined with human umbilical cord mesenchymal stem cells (UC-MSCs) in patients with severe aplastic anemia (SAA), but also investigated the factors related to graft versus host disease (GVHD). Cotransplantation of haplo-HSCs and UC-MSCs was performed in 24 SAA patients. The conditioning regimens consisted of rabbit anti-human T-lymphocyte immunoglobulin (ATG), cyclophosphamide, and fludarabine with or without busulfan. GVHD was prevented using cyclosporine A, ATG, anti-CD25 monoclonal antibody, and mycophenolate material. The incidence of acute GVHD was 50%. The incidence of severe acute GVHD was not related to gender, age, donor-recipient relations, and patient/donor pair, while patient/donor pair (r = 0.541, P = 0.022) was significantly correlated with incidence of chronic GVHD. Upon follow-up for a median of 13 months, 5 of the 24 patients (20.8%) were dead. The survival rates at 3 and 6 months in all patients were 87.5% (21/24) and 83.3% (20/24), respectively. Cotransplantation of haplo-HSCs combined with UC-MSCs was an effective and safe approach for the treatment of patients with SAA. The appropriate conditioning regimen and early treatment for infection also played a critical role in the success of HSCT.
- 1 March 2018
- Published by Springer Nature in European Journal of Medical Research
- Vol. 23 (1) , 1-8
Open AccessClinical evaluation of haploidentical hematopoietic combined with human umbilical cord-derived mesenchymal stem cells in severe aplastic anemia
This study not only evaluated the clinical effects of treatment using haploidentical hematopoietic stem cells (haplo-HSCs) combined with human umbilical cord mesenchymal stem cells (UC-MSCs) in patients with severe aplastic anemia (SAA), but also investigated the factors related to graft versus host disease (GVHD). Cotransplantation of haplo-HSCs and UC-MSCs was performed in 24 SAA patients. The conditioning regimens consisted of rabbit anti-human T-lymphocyte immunoglobulin (ATG), cyclophosphamide, and fludarabine with or without busulfan. GVHD was prevented using cyclosporine A, ATG, anti-CD25 monoclonal antibody, and mycophenolate material. The incidence of acute GVHD was 50%. The incidence of severe acute GVHD was not related to gender, age, donor-recipient relations, and patient/donor pair, while patient/donor pair (r = 0.541, P = 0.022) was significantly correlated with incidence of chronic GVHD. Upon follow-up for a median of 13 months, 5 of the 24 patients (20.8%) were dead. The survival rates at 3 and 6 months in all patients were 87.5% (21/24) and 83.3% (20/24), respectively. Cotransplantation of haplo-HSCs combined with UC-MSCs was an effective and safe approach for the treatment of patients with SAA. The appropriate conditioning regimen and early treatment for infection also played a critical role in the success of HSCT.